Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Last Hour:
Last 24 Hours:

Global Raynauds Disease Market 2016 Share, Trend, Segmentation and Forecast to 2022

Monday, October 10, 2016 4:20
% of readers think this story is Fact. Add your two cents.

(Before It's News)


Global Markets Direct’s, ‘Raynauds Disease – Pipeline Review, H2 2016’, provides an overview of the Raynauds Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Raynauds Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Raynauds Disease and features dormant and discontinued projects.

Complete report details @

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


- The report provides a snapshot of the global therapeutic landscape of Raynauds Disease 
- The report reviews pipeline therapeutics for Raynauds Disease by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Raynauds Disease therapeutics and enlists all their major and minor projects 
- The report assesses Raynauds Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Raynauds Disease

Request a sample report @

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies 
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Raynauds Disease 
- Identify potential new clients or partners in the target demographic 
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics 
- Devise corrective measures for pipeline projects by understanding Raynauds Disease pipeline depth and focus of Indication therapeutics 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope 
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Make an enquiry before buying this Report @

Key points in table of content

Table of Contents 
Table of Contents 2 
List of Tables 4 
List of Figures 4 
Introduction 5 
Global Markets Direct Report Coverage 5 
Raynauds Disease Overview 6 
Therapeutics Development 7 
Pipeline Products for Raynauds Disease – Overview 7 
Raynauds Disease – Therapeutics under Development by Companies 8 
Raynauds Disease – Pipeline Products Glance 9 
Late Stage Products 9 
Clinical Stage Products 10 
Early Stage Products 11 
Raynauds Disease – Products under Development by Companies 12 
Raynauds Disease – Companies Involved in Therapeutics Development 13 
Allergan Plc 13 
Apricus Biosciences, Inc. 14 
Covis Pharmaceuticals, Inc. 15 
Human Stem Cells Institute 16 
Raynauds Disease – Therapeutics Assessment 17 
Assessment by Monotherapy Products 17 
Assessment by Target 18 
Assessment by Mechanism of Action 20 
Assessment by Route of Administration 22 
Assessment by Molecule Type 24 
Drug Profiles 26 
acetylcysteine – Drug Profile 26 
Product Description 26 
Mechanism Of Action 26 
R&D Progress 26 
alprostadil – Drug Profile 27 
Product Description 27 
Mechanism Of Action 27 
R&D Progress 27 
ELS-140 – Drug Profile 34 
Product Description 34 
Mechanism Of Action 34 
R&D Progress 34 
Neovasculgen – Drug Profile 35 
Product Description 35 
Mechanism Of Action 35 
R&D Progress 35 
nitroglycerin – Drug Profile 36 
Product Description 36 
Mechanism Of Action 36 
R&D Progress 36 
onabotulinumtoxin A – Drug Profile 38 
Product Description 38 
Mechanism Of Action 38 
R&D Progress 38 
Raynauds Disease – Dormant Projects 43 
Raynauds Disease – Discontinued Products 44 
Raynauds Disease – Product Development Milestones 45 
Featured News & Press Releases 45 
Mar 08, 2016: Apricus Biosciences to Present at the 28th Annual ROTH Conference 45 
Feb 02, 2016: Apricus Biosciences to Present at the 18th Annual BIO CEO & Investor Conference, Provide Update on Vitaros 45 
Aug 05, 2015: Apricus Biosciences to Provide Update On The European Launch of Vitaros at the Canaccord Genuity 35th Annual Growth Conference 45 
Apr 28, 2015: Apricus Biosciences to Present at Two Investor Conferences in May 45 
Jan 27, 2015: Apricus Biosciences Announces Issuance of U.S. Patent for RayVa 46 
Dec 04, 2014: Apricus Biosciences Announces First Patient Enrolled In Phase 2a Clinical Trial For RayVa In Patients With Raynaud’s Phenomenon 46 
Oct 13, 2014: Apricus Biosciences Announces Notice of Allowance of U.S. Patent Application for RayVa 47 
Oct 01, 2014: Apricus Biosciences to Present at the 13th Annual BIO Investor Forum 48 
May 12, 2014: Apricus Biosciences Receives FDA Clearance to Begin Clinical Trial of RayVa for Secondary Raynaud’s Phenomenon 48 
Dec 13, 2012: MediQuest Therapeutics To Conduct Meetings At J.P. Morgan Conference Regarding Phase III Topical Formulation Vascana 48 
May 31, 2011: Apricus Bio Receives Israeli Patent For RayVa For Raynaud’s Phenomenon 49 
Apr 13, 2011: Apricus Bio Files For Orphan Drug Designation For RayVa 49 
Sep 22, 2010: FDA Guides Apricus Bio On RayVa’s Approvability For Raynaud’s Syndrome Secondary To Scleroderma 50 
Jan 10, 2006: MediQuest Therapeutics Receives Special Protocol Assessment From The U.S. FDA 50 
Appendix 52 
Methodology 52 
Coverage 52 
Secondary Research 52 
Primary Research 52 
Expert Panel Validation 52 
Contact Us 52 
Disclaimer 53

List of Tables 
Number of Products under Development for Raynauds Disease, H2 2016 7 
Number of Products under Development by Companies, H2 2016 8 
Comparative Analysis by Late Stage Development, H2 2016 9 
Comparative Analysis by Clinical Stage Development, H2 2016 10 
Comparative Analysis by Early Stage Development, H2 2016 11 
Products under Development by Companies, H2 2016 12 
Raynauds Disease – Pipeline by Allergan Plc, H2 2016 13 
Raynauds Disease – Pipeline by Apricus Biosciences, Inc., H2 2016 14 
Raynauds Disease – Pipeline by Covis Pharmaceuticals, Inc., H2 2016 15 
Raynauds Disease – Pipeline by Human Stem Cells Institute, H2 2016 16 
Assessment by Monotherapy Products, H2 2016 17 
Number of Products by Stage and Target, H2 2016 19 
Number of Products by Stage and Mechanism of Action, H2 2016 21 
Number of Products by Stage and Route of Administration, H2 2016 23 
Number of Products by Stage and Molecule Type, H2 2016 25 
Raynauds Disease – Dormant Projects, H2 2016 43 
Raynauds Disease – Discontinued Products, H2 2016 44

Get this report @

Contact US:


Partner Relations & Marketing Manager

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.